Skip to main content
main-content

22-10-2018 | Non-small-cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

More on this topic

Thoracic cancers in the 2020 ASCO Virtual Scientific Program

All the news and expert video interviews from the virtual meeting

Image Credits